Business Daily Media

Men's Weekly

.

Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations

  • Brings over 20 years of clinical experience, including management of Phase 1-2 clinical trials in a variety of indications such as ophthalmology
  • Will oversee all R&D operations with focus on clinical development and operations

Kensington, MD, USA - EQS Newswire - 25 October 2023 - Galimedix Therapeutics, Inc.

("Galimedix"), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, today announced the appointment of Luciana Summo, PhD, as Vice President, R&D Operations. In this newly created position, she will oversee all activities related to R&D operations, with an emphasis on clinical development and operations. This includes spearheading the design, planning, and execution of clinical trials. Dr. Summo reports to Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer.

"We are delighted to welcome Luciana to Galimedix," said Alexander Gebauer, MD, PhD, Co-founder and Executive Chairman. "She brings strong experience setting up and running clinical trials and ensuring that all of the proper support structures are put in place. As we move our lead product candidate, GAL-101, into Phase 2 testing for the treatment of dry age-related macular degeneration, her skill set is the perfect fit for this next stage in our development. Luciana will play a pivotal role in defining Galimedix's overall R&D strategy and driving our R&D initiatives forward. All of us very much look forward to working with her as we contribute to advancing innovative healthcare solutions that have the potential to improve the lives of patients."

Dr. Summo has over 20 years of experience in clinical development and operations, including the management of Phase 1-2 clinical trials in several indications such as ophthalmology, cardiology, and oncology. Prior to joining Galimedix, she worked in positions of increasing responsibility in the clinical departments at OMEICOS Therapeutics GmbH, NOXXON Pharma AG, and Berlin-Chemie AG/ Menarini Group. She is well versed in setting up and overseeing clinical trials on a global scale and has played a key role in transitioning programs from pre-clinical to clinical stage. She has experience with the entire spectrum of activities related to R&D operations, with a special emphasis on clinical development and clinical operations, including also quality management and CMC. She works closely with cross-functional teams, including CROs, scientists, clinicians, regulatory affairs specialists, and different stakeholders, to ensure that trials are conducted in accordance with rigorous scientific standards and regulatory guidelines. Dr. Summo has experience in submitting Clinical Trial Applications (CTAs) in Europe and Investigational New Drug (IND) applications in the US and prepared for and participated in pre-IND meetings with the US Food and Drug Administration (FDA), as well as regulatory agency meetings in Europe. She also has set up from scratch and run a clinical operations department.

Luciana Summo, PhD, Vice President, R&D Operations, added: "I am truly excited to be joining Galimedix at this important point in the Company's growth. The programs in ophthalmology and Alzheimer's disease have the potential to change the treatment paradigm, and I look forward to working with the rest of the team to bring them forward in the clinic."
Hashtag: #Galimedix

The issuer is solely responsible for the content of this announcement.

About Galimedix Therapeutics, Inc.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix's groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and Alzheimer's disease - Galimedix's initial areas of focus. The Company's approach targets toxic Aβ oligomers and protofibrils. Many studies have indicated that these oligomers and protofibrils are an underlying cause of neurodegenerative diseases of the eye. And, recent approvals and promising Phase 3 results of anti-Aβ drugs also have validated them as a key target in Alzheimer's disease. Compelling pre-clinical data support the potential of Galimedix's product candidates to slow or stop neurodegeneration and also restore lost neuronal function. A Phase 2 proof-of-concept study in dry AMD with lead program, topical GAL-101, is in preparation with strong support from partner, Théa Open Innovation (TOI). Clinical studies in other indications are planned.

News from Asia

Wildberries tests ready-to-eat food delivery from restaurants

MOSCOW, RUSSIA - Media OutReach Newswire - 16 July 2025 - Wildberries, a leading digital platform in Eurasia, is launching a pilot service for express delivery of ready-made meals from restaurants...

MSIG Hong Kong’s 2024 Claims Report announces multi-year growth in its claims settlement ratio and highlights award-winning claims processing innovation

94.5% claims settlement ratio was achieved amidst a difficult business environment First year that two categories – Employees' Compensation Hong Kong and Marine - saw settlement ratios of 100% D...

Johnson Electric reports Business and Unaudited Financial Information for the First Quarter of Financial Year 25/26 and Formation of Joint Ventures in the PRC for Humanoid Robotics Business

HONG KONG SAR - Media OutReach Newswire – 16 July 2025 - This news release is made by Johnson Electric Holdings Limited ("Johnson Electric" or the "Company" and together with its subsidiaries, the...

Biotech Breakthroughs in Anti-Aging: Decoding the Hallmarks of Aging and the Longevity Code

The Hong Kong Society of Cosmetic Chemists (HKSCC) Invites Swiss Biotech Expert to unveil scientific truths behind aging Clinical Evidence Confirms Anti-Aging Efficacy of Plant-Based Stem ...

This Summer, Take a Break with a Brick. Join LEGO® Group and Minifigure "Lok Jai" on a Joyful Journey Across 8 "Fun Spots" Explore Hong Kong’s Map of Happiness and Make the Most of Your Holiday

HONG KONG SAR - Media OutReach Newswire - 16 July 2025 - This summer, LEGO® Group teams up with popular minifigure Lok Jai to invite everyone in Hong Kong—young and old—to "Take a Brick" and enjoy...

SY Holdings Issues Positive Profit Alert for 1H 2025: Net Profit Expected to increase by approximately 20%, Platform-Based Tech Revenue Share Surpasses 50%

SHENZHEN, CHINA - EQS Newswire - 16 July 2025 - SY Holdings Group Limited ("SY Holdings" or the "Group", Stock Code: 6069.HK), a leading digital-intelligence technology company focused on "AI + Ind...

SUNRATE Awarded In CNBC’s World’s Top Fintech Companies 2025 List

SINGAPORE - Media OutReach Newswire - 17 July 2025 - SUNRATE, the global payment and treasury management platform, announced today that it has been included in the prestigious CNBC's list of the W...

Reshaping Global Lubricant Supply Chains: Trump-Era Tariffs Driving Industry Pivot Toward Asia

SINGAPORE - Media OutReach Newswire - 17 July 2025 - With the global lubricants industry still adjusting to the lasting impact of U.S. trade policy enacted during the first presidential term ...

Southco Adds New Options To Its E5 Line Of Cam Latches

HONG KONG SAR - Media OutReach Newswire - 17 July 2025 - Southco is adding two new options to its E5 line of quarter-turn cam latches, opening up a variety of new functionalities...

EPIC 2025 Outdid Itself with Record-High 1,200 Applications

Doubled from last year with 87% entering the Hong Kong startup competition from overseas HONG KONG SAR - Media OutReach Newswire - 17 July 2025 - EPIC 2025, organised by Hong Kong Science and Tech...

Australian Businesses Still Stuck in the AI Hype Cycle

Data Governance Failures, ROI Gaps and Unclear Strategy Slowing Progress Despite artificial intelligence (AI) dominating headlines and boardroom ag...

How to ensure your manufacturing business survives international tariff turmoil

Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...

Why Apptio is Enhancing Visibility into AI and Hybrid Cloud

AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...

Beyond borders: Building a scalable strategy for international hiring

For many Australian businesses, growth increasingly depends on thinking beyond local borders.  As wage pressures rise, and specialised talent pool...

The Next Generation of Maritime Sustainable Solutions

As organizations globally seek innovative ways to improve sustainability and their impact on Earth, the American Waterways Operators (AWO), a lead...

Demand for Home Batteries surges as Federal Rebate Kicks In

A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

Sell by LayBy